{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-169252","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2022-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.892830+00:00","generated_at":"2026-06-25T03:59:38.362128+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spero pays $54.5M to terminate HCR revenue interest agreement, regains Tebi asset rights","bullets":["Cash payment of $54.5M (exact $54,484,895) on June 7, 2022 to terminate HCR financing agreement and release all liens.","All rights to tebipenem (Tebi) assets revert to Spero; company previously ceased Tebi commercialization on May 3, 2022.","Contingent additional payment of up to $10M+ if a change of control occurs by Dec 31, 2022, based on equity value."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-169252","json":"https://secwatch.observer/filing/0001193125-22-169252.json","markdown":"https://secwatch.observer/filing/0001193125-22-169252.md","text":"https://secwatch.observer/filing/0001193125-22-169252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522169252/0001193125-22-169252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522169252/d271182d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:59:38.362128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}